GlobeNewswire by notified

Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review

Share
  • The TENDU interim safety results from nine patients show no safety concerns
  • Trial extended to enroll up to three additional patients at the highest dose level
  • TENDU designed to evaluate the Tetanus-Epitope Targeting (TET)-platform in patients with prostate cancer

Oslo, 18August 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, has completed treatment of three patients at the highest dose cohort in the phase I TENDU trial without any safety concerns. Based on these results, the company plans to enroll up to three additional patients at the highest dose level.

The Drug Safety Monitoring Board, a group of experts set up to monitor patient safety during a clinical trial, found no safety concerns in any of the three dose cohorts. A total of nine patients have now been treated; three at each dose level (40 mcg, 400 mcg and 960 mcg). Ultimovacs plans to enroll up to three additional patients at the highest dose level (960 mcg) providing a broader base of early safety data for the TET platform.

“We are very encouraged by the continuing progress of the phase I safety evaluation of the TET platform. With no safety concerns at any dose, we have decided to enroll up to three additional patients at the highest dose level, providing extended data from TENDU on the safety and tolerability of TET for prostate cancer patients.” said Jens Bjørheim, Chief Medical Officer of Ultimovacs. “The data from TENDU, in turn, may provide insights that are useful in Ultimovacs’ broader plans for the development of the TET platform.”

The TET platform, an innovative adjuvant technology, allows for the design and production of multiple therapeutic cancer vaccines. It can potentially be used to strengthen and increase T cell responses to cancer cells by targeting antigens that are specific to one type of cancer or common to many tumor types. The vaccine used in the TENDU study contains prostate cancer-specific antigens. By combining cancer antigens and the vaccine adjuvant in the same molecule, the TET platform can generate vaccine candidates with a potential beneficial safety and administration profile, including presenting an opportunity to treat patients at an earlier stage of their disease.

The TENDU study is a first-in-human, dose-escalation study designed to generate initial safety and immune activation data. This study is investigating a prostate cancer-specific therapeutic TET-based vaccine in patients who have relapsed following radical prostatectomy.

==ENDS==

About the TET-platform
All vaccines consist of two components, adjuvant and antigen. The adjuvant activates the immune system so that a relevant immune response can occur. The antigen directs the quality of the immune response. Together the adjuvant and the antigen ensure a specific and effective immune response.

The Tetanus-Epitope Targeting (TET)-platform offers an approach to strengthen and increase T cell responses against cancer-specific peptides by combining cancer-specific antigens and vaccine adjuvant in the same conjugated molecule, allowing for a beneficial safety profile and simplifying administration. The platform generates new, first-in-class cancer vaccine candidates that harness pre-existing antibody responses resulting from standard tetanus vaccinations. TET vaccine candidates can be tailored to many types of cancer, and to infectious diseases.

About TENDU
The TENDU clinical trial (NCT04701021) is a first-in-human, phase I study and the first clinical trial of a vaccine from Ultimovacs' Tetanus-Epitope Targeting (TET)-platform. The trial is being conducted at the Oslo University Hospital, Norway, and evaluates the safety of the vaccine in prostate cancer patients who have relapsed after radical prostatectomy. The primary objective of the study is to evaluate the safety and tolerability of three different doses of the vaccine. Patients will receive the vaccine prior to obtaining standard-of-care treatment consisting of radiation and antihormone therapy and will be followed for 6 months after the last dose of the vaccine to assess immunological responses such as the activation of T cells and anti-tumor activity.

About Ultimovacs
Ultimovacs is an immunotherapy company developing immune-stimulatory vaccines to treat a broad range of cancers. Ultimovacs’ lead universal cancer vaccine candidate UV1 targets human telomerase (hTERT), present in 85-90% of cancers in all stages of tumor growth. By directing the immune system to hTERT antigens, UV1 drives CD4 helper T cells to the tumor to activate an immune system cascade and increase anti-tumor responses. With a broad phase II program in five cancer indications enrolling more than 650 patients, Ultimovacs aims to clinically demonstrate UV1’s impact in multiple cancer types, in combination with other immunotherapies, for patients with unmet needs. Ultimovacs’ second technology approach, based on the proprietary Tetanus-Epitope-Targeting (TET) platform, combines tumor-specific peptides and adjuvant in the same molecule and entered phase I studies in 2021.

For further information, please see www.ultimovacs.com or contact:

Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507

Anne Worsøe, Head of IR & Communication
Email: anne.worsoe@ultimovacs.com
Phone: +47 90686815

Mary-Ann Chang, LifeSci Advisors
Email: mchang@lifesciadvisors.com
Phone: +44 7483 284 853

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Joachim Midttun, Finance Manager at Ultimovacs ASA, on 18August, 2022 at 08:00 CET.


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Webtel.mobi publishes a detailed article on why the US Dollar is not under threat as Global Reserve Currency, nor a consideration for Global Financial Reform28.3.2024 13:00:46 CET | Press release

NEW YORK and LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Global Telephony Provider Webtel.mobi has published a detailed article describing the real issue and remedy for achievement of Global Financial Reform, required to end the regular “Boom and Bust” cycles. Additionally, a public version of the article follows below Speculation as to the potential ending of the US Dollar’s reign as Global Reserve Currency – or the necessity of that – are both misplaced, according to the Global Telecommunications Company Webtel.mobi. This is, it says, because it is not a Global Currency (any one of them) that creates any global imbalances, weighted advantages or potential reform solutions. It is rather the Global System over which all currencies are transacted that creates all global imbalances, weighted advantages or potential reform solutions. The current Global System is relatively young. It came into being after the end of World War Two, and was provided to the world (or imposed on the world – dep

Digitalist Group Plc has published Financial Statements of 2023, Report by the Board of Directors, Auditor’s Report, Corporate Governance Statement and Remuneration Report28.3.2024 13:00:00 CET | Press release

Digitalist Group Plc Stock Exchange Release 28 March 2024 at 14:00 Digitalist Group Plc has published Financial Statements of 2023, Report by the Board of Directors, Auditor’s Report, Corporate Governance Statement and Remuneration Report Digitalist Group Plc has published the Financial Statements of 2023, the Report by the Board of Directors, the Auditor’s Report, the Corporate Governance Statement and the Remuneration Report in company’s internet pages mentioned below: The financial statements of 2023, which include the Board of Directors' report and the Auditor's report, are published at https://investor.digitalistgroup.com/investor/financial/financial-statements. The Corporate Governance Statement is published at https://investor.digitalistgroup.com/investor/governance. The Remuneration Report is published at https://investor.digitalistgroup.com/investor/governance/remuneration. The Financial Statements of 2023 which include the Board of Directors' report and the Auditor's report,

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors28.3.2024 13:00:00 CET | Press release

David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a New Chair LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that Board Chair and co-founder George Goldsmith and fellow co-founder Ekaterina Malievskaia have resigned their seats on the company’s board of directors, effective March 29, 2024. David Norton, lead independent director on the Compass board of directors, will become interim chair. Compass is running a global search for a permanent board chair, focused on recruiting a leader with a strong background in the biotechnology sector and broad strategic experience across the product lifecycle. “When we started Compass eight years ago, we could not have imagined how the company would grow and mature,” said George Goldsmith, outgoing board chair of Compass Pathways. “The comp

Allied Industrial Partners-Backed CES Power Acquires ABird/Apex Power Solutions28.3.2024 12:45:10 CET | Press release

11th Bolt-on Acquisition Expands CES Power’s Global Presence Providing Significant Scale in the U.K. and Europe MEMPHIS, Tenn. and LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- CES Power LLC (“CES Power”), a leading global provider of sustainable mobile power generation, distribution, temperature control and technology solutions for the largest and most complex projects and events, today announced that it has acquired ABird Limited and Apex Generators Limited (“ABird/Apex” or “the Company”), a U.K. supplier of portable power for industrial, corporate and event use. The acquisition was made through CES Power’s global division, CES Global LLC (“CES Global”), which acquired ABird/Apex from U.K. tool and equipment rental and services company HSS Hire Group Plc (LSE: HSS). CES Power is backed by industrial-focused private equity firm Allied Industrial Partners (“Allied”). This strategic acquisition will expand CES Global’s capacity in the U.K. and Ireland while helping to accelerate its growth

CONDITIONS FOR RIKSBANK AUCTIONS GOVERNMENT BONDS28.3.2024 12:05:00 CET | Press release

Bid procedure, 2024-04-05BondsSWEDISH GOVERNMENT: 1060. SE0009496367. 2028-05-12 SWEDISH GOVERNMENT: 1062, SE0013935319, 2031-05-12 SWEDISH GOVERNMENT: 1053, SE0002829192, 2039-03-30 Bid date2024-04-05Bid times09.00-10.00 (CET/CEST) on the Bid dateOffered volume (corresponding nominal amount)1060: 900 million SEK +/-900 million SEK 1062: 900 million SEK +/-900 million SEK 1053: 900 million SEK +/-900 million SEK Highest permitted bid volume (corresponding nominal amount)1060: 900 million SEK per bid 1062: 900 million SEK per bid 1053: 900 million SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 10 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2024-04-09Settlement amountTo be paid to the Riksbank's account in Euroclear Sweden AB's securities settlement system SWIFT: VPCSSESSXXX Account: 1 4948 6383 CTM BIC: RIKSSESS ALERT acronym: RIKSBANK Stockholm, 2024-03-28 This is a translation of the special

HiddenA line styled icon from Orion Icon Library.Eye